Format

Send to

Choose Destination
Therap Adv Gastroenterol. 2010 Nov;3(6):349-57. doi: 10.1177/1756283X10377126.

Managing bile acid diarrhoea.

Author information

1
Section of Hepatology and Gastroenterology, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.

Abstract

Bowel symptoms including diarrhoea can be produced when excess bile acids (BA) are present in the colon. This condition, known as bile acid or bile salt malabsorption, has been under recognized, as the best diagnostic method, the (75)Se-homocholic acid taurine (SeHCAT) test, is not available in many countries and is not fully utilized in others. Reduced SeHCAT retention establishes that this is a complication of many other gastrointestinal diseases. Repeated studies show SeHCAT tests are abnormal in about 30% of patients otherwise diagnosed as diarrhoea-predominant irritable bowel syndrome or functional diarrhoea, with an estimated population prevalence of around 1%. Recent work suggests that the condition previously called idiopathic bile acid malabsorption (BAM) is not in fact due to a defect in absorption, but results from an overproduction of BA because of defective feedback inhibition of hepatic bile acid synthesis, a function of the ileal hormone fibroblast growth factor 19 (FGF19). The approach to treatment currently depends on binding excess BA, to reduce their secretory actions, using colestyramine, colestipol and, most recently, colesevelam. Colesevelam has a number of potential advantages that merit further investigation in trials directed at patients with bile acid diarrhoea.

KEYWORDS:

Crohn's disease; SeHCAT; bile acids; colesevelam; colestipol; colestyramine; fibroblast growth factor 19; functional diarrhoea; irritable bowel syndrome; malabsorption

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center